- Home
- CNSP vs OGEN Comparison
CNSP vs OGEN Comparison
Compare CNSP & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNSP
- OGEN
- Stock Information
- Founded
- CNSP 2017
- OGEN 1996
- Country
- CNSP United States
- OGEN United States
- Employees
- CNSP N/A
- OGEN N/A
- Industry
- CNSP Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CNSP Health Care
- OGEN Health Care
- Exchange
- CNSP Nasdaq
- OGEN Nasdaq
- Market Cap
- CNSP 5.6M
- OGEN 4.6M
- IPO Year
- CNSP 2019
- OGEN N/A
- Fundamental
- Price
- CNSP $0.84
- OGEN $4.13
- Analyst Decision
- CNSP Hold
- OGEN
- Analyst Count
- CNSP 1
- OGEN 0
- Target Price
- CNSP N/A
- OGEN N/A
- AVG Volume (30 Days)
- CNSP 228.7K
- OGEN 656.3K
- Earning Date
- CNSP 08-13-2025
- OGEN 08-08-2025
- Dividend Yield
- CNSP N/A
- OGEN N/A
- EPS Growth
- CNSP N/A
- OGEN N/A
- EPS
- CNSP N/A
- OGEN N/A
- Revenue
- CNSP N/A
- OGEN N/A
- Revenue This Year
- CNSP N/A
- OGEN N/A
- Revenue Next Year
- CNSP N/A
- OGEN N/A
- P/E Ratio
- CNSP N/A
- OGEN N/A
- Revenue Growth
- CNSP N/A
- OGEN N/A
- 52 Week Low
- CNSP $0.73
- OGEN $3.12
- 52 Week High
- CNSP $148.00
- OGEN $75.60
- Technical
- Relative Strength Index (RSI)
- CNSP 38.65
- OGEN 47.04
- Support Level
- CNSP $0.73
- OGEN $3.41
- Resistance Level
- CNSP $0.84
- OGEN $4.85
- Average True Range (ATR)
- CNSP 0.07
- OGEN 0.58
- MACD
- CNSP 0.00
- OGEN 0.01
- Stochastic Oscillator
- CNSP 31.47
- OGEN 42.49
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.